BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29530581)

  • 21. Treatment and management strategies of onychomycosis.
    Aggarwal R; Targhotra M; Kumar B; Sahoo PK; Chauhan MK
    J Mycol Med; 2020 Jun; 30(2):100949. PubMed ID: 32234349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug delivery to the nail: therapeutic options and challenges for onychomycosis.
    Barot BS; Parejiya PB; Patel HK; Mehta DM; Shelat PK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(6):459-94. PubMed ID: 25271773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Drug Delivery Strategies for the Treatment of Onychomycosis.
    Dhamoon RK; Popli H; Gupta M
    Pharm Nanotechnol; 2019; 7(1):24-38. PubMed ID: 31092174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and development of a safer non-invasive transungual drug delivery system for topical treatment of onychomycosis.
    Pal P; Thakur RS; Ray S; Mazumder B
    Drug Dev Ind Pharm; 2015; 41(7):1095-9. PubMed ID: 24980914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties.
    Kerai LV; Hilton S; Maugueret M; Kazi BB; Faull J; Bhakta S; Murdan S
    Int J Pharm; 2016 Nov; 514(1):244-254. PubMed ID: 27863669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
    Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
    J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contemporary Techniques and Potential Transungual Drug Delivery Nanosystems for The Treatment of Onychomycosis.
    Abd-Elsalam WH; Abouelatta SM
    AAPS PharmSciTech; 2023 Jul; 24(6):150. PubMed ID: 37421509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1st meeting on topical drug delivery to the nail.
    Murdan S
    Expert Opin Drug Deliv; 2007 Jul; 4(4):453-5. PubMed ID: 17683257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Polyurethane Nail Lacquers for the Delivery of Terbinafine: Formulation and Antifungal Activity Evaluation.
    Gregorí Valdes BS; Serro AP; Gordo PM; Silva A; Gonçalves L; Salgado A; Marto J; Baltazar D; Dos Santos RG; Bordado JM; Ribeiro HM
    J Pharm Sci; 2017 Jun; 106(6):1570-1577. PubMed ID: 28263845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis.
    Nair AB; Kim HD; Chakraborty B; Singh J; Zaman M; Gupta A; Friden PM; Murthy SN
    J Pharm Sci; 2009 Nov; 98(11):4130-40. PubMed ID: 19340887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis.
    Tanrıverdi ST; Özer Ö
    Eur J Pharm Sci; 2013 Mar; 48(4-5):628-36. PubMed ID: 23295582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation.
    Tanrıverdi ST; Hilmioğlu Polat S; Yeşim Metin D; Kandiloğlu G; Özer Ö
    J Liposome Res; 2016; 26(2):163-73. PubMed ID: 26226352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.
    Naeimifar A; Samadi A; Ahmad Nasrollahi S; Fattahi A; Ghasemi Z; Azizzadeh-Roodpishi S; Malakooti S; Ehsani AH; Firooz A; Dowlatiy Y
    Mycoses; 2020 May; 63(5):517-524. PubMed ID: 32048351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
    Cutrín Gómez E; Anguiano Igea S; Delgado-Charro MB; Gómez Amoza JL; Otero Espinar FJ
    Eur J Pharm Biopharm; 2018 Jul; 128():48-56. PubMed ID: 29673870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases.
    Bellmann T; Luber R; Kischio L; Karl B; Pötzinger Y; Beekmann U; Kralisch D; Wiegand C; Fischer D
    Int J Pharm; 2022 Nov; 628():122267. PubMed ID: 36209980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iontophoresis to Overcome the Challenge of Nail Permeation: Considerations and Optimizations for Successful Ungual Drug Delivery.
    Chen K; Puri V; Michniak-Kohn B
    AAPS J; 2021 Jan; 23(1):25. PubMed ID: 33439400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Patents on Permeation Enhancers for Drug Delivery Through Nails.
    Kreutz T; de Matos SP; Koester LS
    Recent Pat Drug Deliv Formul; 2019; 13(3):203-218. PubMed ID: 31663846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of hot-melt extruded drug delivery systems for onychomycosis.
    Mididoddi PK; Repka MA
    Eur J Pharm Biopharm; 2007 Apr; 66(1):95-105. PubMed ID: 17045468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.